Phase I trial of i.v. administered tirapazamine plus cyclophosphamide

Anti-Cancer Drugs

Volumn 12, Issue 6, 2001, Pages 499-503

  Hoff, Paulo M ^a,d   Saad, Everardo D ^a   Ravandi Kashani, Farhad ^a   Czerny, Elizabeth ^b   Pazdur, Richard ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Sanofi Research Division   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d Box 426 ^*  (United States)

Author keywords

Cyclophosphamide; Hypoxia; Phase I trial; Solid tumors; Tirapazamine

Indexed keywords

AMINOTRANSFERASE; CREATINE KINASE; CYCLOPHOSPHAMIDE; MITOMYCIN C; NITROSOUREA; TIRAPAZAMINE;

ADULT; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG FEVER; DRUG TISSUE LEVEL; DRUG TOLERANCE; FATIGUE; GRANULOCYTOPENIA; HEADACHE; HEARING IMPAIRMENT; HUMAN; LEUKOCYTE COUNT; MAXIMUM TOLERATED DOSE; NAUSEA; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TIME FACTORS; TRIAZINES;

EID: 0034922176     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200107000-00002     Document Type: Article

References (32)

1. Definitive evidence for hypoxic cells influencing cure in cancer therapy
2. Relationship between size and oxygenation status of malignant tumors
3. Blood flow, tissue oxygenation, and pH-distribution in malignant tumors upon localized hyperthermia. Basic pathophysiological aspects and the role of various thermal doses
4. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts
5. Hyperbaric oxygen in radiation therapy: The role of respiratory hyperoxia
6. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
7. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine
8. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia
9. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
10. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours
11. Interaction of Sr-4233 with hyperthermia and radiation in the fsaiic murine fibrosarcoma tumor system in vitro and in vivo
12. Enhancement of alkylating agent activity by Sr-4233 in the fsaiic murine fibrosarcoma
13. Interaction between tirapazamine (SR 4233) and cisplatin
14. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts
15. Melphalan enhances the cytotoxicity of tirapazamine under hypoxic but not aerobic conditions
16. Cytotoxicity of bioreductive agents tirapazamine (SR4233) and mitomycin C (MMC) in human ovarian carcinoma cell lines
17. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin
18. Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations
19. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice
20. SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells
21. Sensitivity to tirapazamine (SR4233) is determined by p450 reductase activity in human breast but not lung cancer cell lines
22. Role of human NADPH: Cytochrome P450 CYP2B gene family in the metabolism of the anticancer bioreductive drug Tirapazamine (WIN59075; SR4233)
23. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)
24. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma
25. Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer
26. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors
27. Tirapazamine with cisplatin: A phase II trial in advanced stage non-small cell lung cancer (NSCLC)
28. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer
29. Phase I and pharmacokinetic study of tirapazamine (SR4233), a highly selective hypoxic cell cytotoxin
30. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation
31. Oxygen transport in tumors: Characteristics and clinical implications
32. Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice